厄洛替尼治疗非小细胞肺癌的临床疗效及对免疫球蛋白水平和T淋巴细胞亚群的影响  

Clinical Effect of Erlotinib on Non-small Cell Lung Cancer and Its Impact on Immunoglobulin Levels and T-lymphocyte Subsets

作　　者：瞿伟丰[1] 

机构地区：[1]江苏省无锡市第三人民医院胸外科,221000

出　　处：《实用心脑肺血管病杂志》2015年第5期73-75,共3页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的探讨厄洛替尼治疗非小细胞肺癌的临床疗效及对免疫球蛋白和T淋巴细胞亚群的影响。方法选取2012年1月—2014年9月无锡市第三人民医院收治的100例非小细胞肺癌患者,随机分为对照组和观察组,每组50例。对照组患者采用吉非替尼治疗,观察组患者采用厄洛替尼治疗。比较两组患者的临床疗效,治疗前后白细胞计数(WBC)、血小板计数(PLT)、免疫蛋白(Ig G、Ig A、Ig M)水平及T淋巴细胞亚群(CD+3、CD+4、CD+8细胞分数和CD+4/CD+8细胞比值)。结果观察组患者完全缓解8例、部分缓解21例、疾病稳定18例、疾病进展3例,对照组患者完全缓解2例、部分缓解11例、疾病稳定25例、疾病进展12例,观察组患者临床疗效优于对照组(P<0.05)。治疗前后两组患者WBC,PLT,Ig G、Ig A、Ig M水平,CD+3、CD+4、CD+8细胞分数及CD+4/CD+8细胞比值比较,差异均无统计学意义(P>0.05)。结论厄洛替尼治疗非小细胞肺癌疗效确切,且对免疫球蛋白水平及T淋巴细胞亚群无明显影响。Objective To investigate the clinical effect of erlotinib on non-small cell lung cancer and its impact on immunoglobulin levels and T-lymphocyte subsets.Methods A total of 100 patients with non-small cell lung cancer were selected in the Third People＇ s Hospital of Wuxi from January 2012 to September 2014,and they were randomly divided into control group and observation group,each of 50 cases.Patients of control group were given gefitinib,while patients of observation group were given erlotinib.Clinical effect,WBC,PLT,Ig G,Ig A,Ig M,CD＋3cell percentage,CD＋4cell percentage,CD＋8cell percentage and CD＋4/ CD＋8cell ratio before and after treatment were compared between the two groups.Results In observation group,8 cases got complete remission,21 cases got partial remission,18 cases got stable disease,3 cases got progressive disease;in control group,2 cases got complete remission,11 cases got partial remission,25 cases got stable disease,12 cases got progressive disease.The clinical effect of observation group was statistically significantly better than that of control group（P〈0.05）.No statistically significant differences of WBC,PLT,Ig G,Ig A,Ig M,CD＋3cell percentage,CD＋4cell percentage,CD＋8cell percentage or CD＋4/ CD＋8cell ratio was found between the two groups before or after treatment（P〉0.05）.Conclusion Erlotinib has certain clinical effect on non-small cell lung cancer,without obvious impact on immunoglobulin levels and T-lymphocyte subsets.

关 键 词：癌 非小细胞肺 厄洛替尼 吉非替尼 免疫球蛋白类 T淋巴细胞亚群 

分 类 号：R730.26[医药卫生—肿瘤]